

MAR 11 2004

In the United States Patent and Trademark Office

Appl. No.: 10/070,039 Confirmation No. 9715
Applicant(s): Alonso-Alija, et al.
Filed: 10/22/2002
TC/A.U.: 1625
Examiner: Reyes, Hector M.

Docket No.: Le A 33 893
Customer No.: 35969

CERTIFICATION OF TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any papers referred to in this certificate as being attached, are being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Date: 11 March 2005


William F. Gray**RESPONSE TO RESTRICTION / ELECTION OF SPECIES REQUIREMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

This is in response to the Office Action dated 01/11/2005. Please amend the above-identified application as follows:

Remarks begin on page 2 of this paper.

Remarks

In response to the restriction and election of species requirements, applicants elect to proceed with prosecution of restriction group II and elects the species of example 72 (page 168). The structure of example 72 is as follows:




In accordance with the examiner's offer to rejoin a method of using the elected compounds in treatment of a specific disease, applicants choose hypertension as the disease to be considered.

Claims 1-4, 6-9, and 12-20 are deemed to read on the elected species.

Respectfully submitted,

Reg. No. 31018
Phone: (203) 812-2712
Date: 11 March 2005


William F. Gray
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175